Outcomes of the Treatment with Glecaprevir/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors
Background The use of direct‐acting antivirals (DAA) has expanded transplantation from hepatitis C viremic donors (HCV‐VIR). Our team has conducted an open‐label, prospective trial to assess outcomes transplanting HCV viremic hearts. Glecaprevir/pibrentasvir (GLE/PIB) was our sole DAA. Methods Seria...
Saved in:
Published in | Clinical transplantation Vol. 34; no. 9; pp. e13989 - n/a |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Denmark
01.09.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
The use of direct‐acting antivirals (DAA) has expanded transplantation from hepatitis C viremic donors (HCV‐VIR). Our team has conducted an open‐label, prospective trial to assess outcomes transplanting HCV viremic hearts. Glecaprevir/pibrentasvir (GLE/PIB) was our sole DAA.
Methods
Serial quantitative hepatitis C virus (HCV) RNA PCR was obtained to assess HCV viral titers. Between January 2018 and June 2019, a total of 50 recipients were transplanted. Of these, 22/50 (44%) were from HCV‐VIR, the remaining 28 from non‐viremic (HCV NON‐VIR) donors. An 8‐week course of GLE/PIB was initiated at 1 week post‐transplant.
Results
There was no difference in demographic or clinical parameters between groups. All 22 recipients of HCV‐VIR transplants became viremic. GLE/PIB was effective in decreasing viremia to undetectable levels by 6 weeks post‐transplant in all patients. The median time to first undetectable HCV quantitative PCR was (4.3 weeks, IQR: 4‐5.7 weeks). All patients demonstrated sustained undetectable viral load through 1‐year follow‐up. There was no difference in survival at one year between HCV NON‐VIR 28/28: (100%) vs HCV‐VIR 21/22 (95%) recipients.
Conclusions
Our center reports excellent outcomes in transplanting utilizing hearts from HCV‐VIR donors. No effect on survival or co‐morbidity was found. An 8‐week GLE/PIB course was safe and effective when initiated approximately 1 week post‐transplant. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0902-0063 1399-0012 |
DOI: | 10.1111/ctr.13989 |